Epidermolysis Bullosa Awareness Week: Achieving Positive Change Through Treatment Innovations and Emerging Therapies
This Epidermolysis Bullosa (EB) Awareness Week, we reflect on the challenges of managing this rare and often devastating group of genetic skin disorders — and recognize how emerging science is reshaping care for this patient population. Because of its complexity, EB presents unique challenges for both patients and clinicians. In addition to the extreme fragility […]
B-VEC FDA Label Expansion for DEB: What It Means for Patients and CliniciansÂ
In May 2023, the FDA approved beremagene geperpavec (B-VEC, Vyjuvek®), the first topical gene therapy for dystrophic epidermolysis bullosa (DEB). Before this milestone, only supportive care was available for patients living with DEB, focusing on wound care and symptom management rather than targeting the disease at its source. With B-VEC, clinicians gained a treatment that […]
